# The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

> **NCT03300427** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 55 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** sacubitril/valsatran
- **DRUG:** valsartan
- **DRUG:** placebo to valsartan
- **DRUG:** placebo to sacubitril/valsartan

## Key facts

- **NCT ID:** NCT03300427
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-05
- **Primary completion:** 2022-03-23
- **Final completion:** 2022-03-23
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03300427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03300427, "The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03300427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*